1. Academic Validation
  2. In vitro and in vivo studies of the non-sedating antihistamine epinastine

In vitro and in vivo studies of the non-sedating antihistamine epinastine

  • Arzneimittelforschung. 1988 Oct;38(10):1446-53.
A Fügner 1 W D Bechtel F J Kuhn J Mierau
Affiliations

Affiliation

  • 1 Department of Pharmacology, Boehringer Ingelheim K.G. Ingelheim/Rhein, Fed. Rep. of Germany.
PMID: 2461715
Abstract

Epinastine (3-amino-9,13b-dihydro-1H-dibenz [c,f]imidazo[1,5-a]azepine hydrochloride, WAL 801 CL) was tested in vitro and in vivo in comparison with Other H1-receptor antagonists. In the guinea pig ileum and in receptor binding studies the test substance showed a high affinity to H1-receptors. The following rank order was determined: WAL 801 CL greater than astemizole greater than terfenadine. These results were confirmed in vivo. The studies were carried out with oral and intravenous administration of WAL 801 CL to assess the inhibition of histamine-induced reactions in the skin or the lung of rats, dogs and guinea pigs. 10- to 100fold antihistaminic doses of WAL 801 CL showed no effect on the sleeping-waking behaviour of cats. From this and Other results it is suggested that the compound does not penetrate in the central nervous system. The action pattern of WAL 801 CL as a non-sedating antihistamine corresponds more to that of terfenadine than that of ketotifen.

Figures
Products